PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) plus BEVACIZUMAB (BEV) IN BEV-NAIVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)

被引：0
|
作者：
Reardon, David [1 ]
Kaley, Thomas [2 ]
Dietrich, Jorg [3 ]
Clarke, Jennifer [4 ]
Dunn, Gavin [5 ]
Lim, Michael [6 ]
Cloughesy, Tim [7 ]
Gan, Hui [8 ]
Park, Andrew [9 ]
Schwarzenberger, Paul [9 ]
Ricciardi, Toni [9 ]
Macri, Mary [9 ]
Ryan, Aileen [9 ]
Venhaus, Ralph [9 ]
机构：
[1] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] Washington Univ, St Louis, MO USA
[6] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[7] Univ Calif Los Angeles, Neurooncol, Los Angeles, CA USA
[8] Austin Hosp, Melbourne, ACT, Australia
[9] Ludwig Inst Canc Res, New York, NY USA
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ATIM-38
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [21] A randomized, multicenter phase 2 study of DSP-7888 dosing emulsion in combination with bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma.
    De Groot, John Frederick
    Cloughesy, Timothy Francis
    Pitz, Marshall W.
    Narita, Yoshitaka
    Nonomura, Takeshi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] A Phase 1b study to evaluate the safety and antitumor activity of MEDI4736 in combination with tremelimumab in patients with advanced NSCLC
    Goldberg, S. B.
    Balmanoukian, A.
    Chaft, J.
    Rizvi, N.
    Sanborn, R. E.
    Rebelatto, M. C.
    Narwal, R.
    Robbins, P. B.
    Gu, Y.
    Karakunnel, J. J.
    Antonia, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S627 - S627
  • [23] Phase I/II clinical trial of regorafenib plus durvalumab (MEDI4736) in patients with chemotherapy-refractory advanced biliary tract cancers.
    Al-Rajabi, Raed Moh'd Taiseer
    Kasi, Anup
    Baranda, Joaquina Celebre
    Saeed, Anwaar
    Li, Haoran
    Bruey, Collin
    Best, Shaun
    Phadnis, Milind A.
    Sun, Weijing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS581 - TPS581
  • [24] SAFETY RESULTS FROM AVAglio, A PHASE III RANDOMIZED STUDY OF BEVACIZUMAB (BEV) PLUS STANDARD COMBINATION TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Saran, Frank
    Chinot, Olivier L.
    Henriksson, Roger
    Mason, Warren
    Wick, Wolfgang
    Nishikawa, Ryo
    Dahr, Sunita
    Hilton, Magalie
    Garcia, Josep
    Cloughesy, Timothy
    NEURO-ONCOLOGY, 2013, 15 : 127 - 128
  • [25] A phase Ib study of the safety and efficacy of atezolizumab (atezo) plus bevacizumab (bev) plus cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)
    Bendell, J.
    Lieu, C.
    Raghav, K. P. S.
    Argiles, G.
    Cubillo, A.
    Qu, X.
    Yan, Y.
    Merchant, M.
    Zeuner, H.
    Gallo, J. D.
    Segal, N. H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] SAFETY AND EFFICACY OF BEVACIZUMAB AND ERLOTINIB FOR RECURRENT GLIOBLASTOMA PATIENTS IN A PHASE II STUDY
    Sathornsumetee, Sith
    Desjardins, Annick
    Vredenburgh, James
    Rich, Jeremy
    Gururangan, Sridharan
    Friedman, Allan
    Friedman, Henry
    Reardon, David
    NEURO-ONCOLOGY, 2008, 10 (05) : 827 - 827
  • [27] Phase 1/2 Study of Mocetinostat and Durvalumab (MEDI4736) in Patients with Advanced Solid Tumors and Non Small Cell Lung Cancer (NSCLC)
    Haigentz, Missak
    Nemunaitis, John
    Johnson, Melissa
    Mohindra, Nisha
    Eaton, Keith
    Patel, Manish
    Awad, Mark
    Faltaos, Demiana
    Chen, Isan
    Christensen, James
    Potvin, Diane
    Neskorik, Tavette
    Levisetti, Matteo
    Garon, Edward
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1073 - S1074
  • [28] Ibrutinib plus durvalumab (MEDI4736) in patients (pts) with relapsed or refractory (R/R) pancreatic adenocarcinoma (PAC): A phase Ib/II multicenter study.
    Borazanci, Erkut Hasan
    Hong, David S.
    Gutierrez, Martin
    Rasco, Drew W.
    Reid, Tony R.
    Veeder, Michael H.
    Tawashi, Ahmed
    Lin, Jennifer
    Dimery, Isaiah W.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [29] A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results
    Okonogi, Noriyuki
    Murata, Kazutoshi
    Yamada, Shigeru
    Habu, Yuji
    Hori, Makoto
    Kurokawa, Tomoya
    Inaba, Yosuke
    Fujiwara, Tadami
    Fujii, Yasuhisa
    Hanawa, Michiko
    Kawasaki, Yohei
    Hattori, Yoko
    Suzuki, Kazuko
    Tsuyuki, Kyoko
    Wakatsuki, Masaru
    Koto, Masashi
    Hasegawa, Sumitaka
    Ishikawa, Hitoshi
    Hanaoka, Hideki
    Shozu, Makio
    Tsuji, Hiroshi
    Usui, Hirokazu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (13)
  • [30] FINAL EFFICACY AND SAFETY RESULTS FROM AVAglio, A PHASE III TRIAL OF BEVACIZUMAB (BEV) PLUS TEMOZOLOMIDE (TMZ) ANDRADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA
    Chinot, Olivier L.
    Wick, Wolfgang
    Mason, Warren
    Henriksson, Roger
    Saran, Frank
    Nishikawa, Ryo
    Carpentier, Antoine F.
    Khe Hoang-Xuan
    Kavan, Petr
    Cernea, Dana
    Brandes, Alba A.
    Hilton, Magalie
    Kerloeguen, Yannick
    Guijarro, Abajo
    Cloughsey, Timothy
    NEURO-ONCOLOGY, 2013, 15 : 105 - 106
12345